問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Digestive System Department

Division of General Internal Medicine

更新時間：2023-09-19

林俊彥Lin, Chun-Yen
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

20Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林俊彥

List

57Cases

2012-10-01 - 2015-04-30

Phase II

An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BMS-650032 Asunaprevir / BMS-790052 Daclatasvir

Participate Sites
8Sites

Terminated8Sites

2013-02-01 - 2016-12-31

Phase III

A Phase 3 Randomized, Double Blind, Regional Multi-National Evaluation of Daclatasvir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects with Chronic Hepatitis C Genotypes 1 and 4

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BMS-790052

Participate Sites
10Sites

Terminated10Sites

2013-01-16 - 2015-07-01

Phase III

A Phase 3 evaluation of daclatasvir in combination with peginterferon lambda-1a and ribavirin (RBV) or telaprevir in combination with peginterferon alfa-2a and RBV in patients with chronic hepatitis C genotype 1b who are treatment naïve or prior relapsers to alfa/RBV therapy(The STRUCTURE Study)

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BMS-914143/ BMS-790052

Participate Sites
6Sites

Terminated6Sites

2014-07-01 - 2015-12-31

Phase III

A Phase 3 Study of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects with Chronic Hepatitis C Genotype 1 (UNITY 4)

  • Condition/Disease

    Chronic Hepatitis C Genotype 1

  • Test Drug

    Daclatasvir/Asunaprevir/BMS-791325; Film coated tablet; 30 mg/200 mg/75 mg (as the free base)

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

2011-03-01 - 2016-06-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    TSU-68

Participate Sites
14Sites

Terminated14Sites

2023-02-15 - 2025-06-30

Phase I

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-2829GS-6779

Participate Sites
10Sites

Recruiting10Sites

2020-06-01 - 2021-05-31

Phase I

A phase I study to evaluate the safety, tolerability, and antitumor activity of neoantigen-expanded autologous immune cell therapy for solid tumors

  • Condition/Disease

    Advanced Solid Tumor

  • Test Drug

    Neoantigen-expanded autologous immune cell

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB